The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step FDA Peptide Regulation and HHS Policy Holt Law FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn Major peptide regulatory news this week. The FDA announced on April 15 that it will remove 12 peptides from Category 2 of the 503A bulk drug substances list after seven calendar days.